Pituitary Neoplasms: Clinical Trials

25 trials for Pituitary Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 8 terminated, 5 withdrawn, 2 unknown. 25 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 225Completed 9, Terminated 8, Withdrawn 5, Unknown 2, Active not recruiting 1
Phase 32Completed 1, Unknown 1
Phase 11Completed 1

Follow Pituitary Neoplasms: new trials by email Literature Review of Pituitary Neoplasms trials Research Report on Pituitary Neoplasms

Trials (filtered) newest first · largest first

All 25 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery
Tranexamic acid, Placebo - Pituitary Tumor, Blood Loss
Phase 2WithdrawnUniversity of North Carolina, Chapel Hill2022-03-012022-04-05
TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas
TBR-760, Placebo - Non-Functional Pituitary Adenoma, Pituitary Tumor, Nonfunctioning
Phase 2UnknownTiburio Therapeutics1502020-05-012020-04-06
The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas
Radiotherapy plus temozolomide, Radiotherapy plus placebo - Pituitary Adenomas
Phase 2 / Phase 3UnknownPeking Union Medical College Hospital1502020-02-102020-01-28
Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
Ipilimumab, Nivolumab - Pituitary, Pituitary Tumor
Phase 2CompletedMemorial Sloan Kettering Cancer Center102019-07-312026-06-02
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
Lutetium Lu 177 Dotatate - Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma
Phase 2WithdrawnM.D. Anderson Cancer Center2019-06-132020-09-07
Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas
Capecitabine, Temozolomide - Recurrent Pituitary Adenomas
Phase 2TerminatedWeill Medical College of Cornell University12019-05-212022-08-09
Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors
Pasireotide LAR - Pituitary Tumor, ACTH-producing Pituitary Tumour
Phase 2TerminatedColumbia University42017-07-102021-04-27
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
Ropinirole - Hyperprolactinemia, Prolactinoma
Phase 1 / Phase 2CompletedColumbia University162016-09-162024-06-04
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
Photofrin photodynamic therapy. - Brain Tumor, Recurrent
Phase 2TerminatedHarry T Whelan, MD12015-06-012019-08-20
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
Pasireotide with or without cabergoline - Cushings Disease
Phase 2TerminatedNovartis Pharmaceuticals682014-03-062020-09-18
Enhancement of Neurocognitive Functions by Hippocampal Sparing Radiotherapy
Radiation according to indication with hippocampal sparing, Radiation according to indication without hippocampal protection - Radiation of Neurocranial Region
Phase 2Active not recruitingUniversity of Erlangen-Nürnberg Medical School1502013-03-012026-10-27
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
Pasireotide LAR - Acromegaly, Pituitary Gigantism
Phase 2CompletedNovartis Pharmaceuticals332012-10-162019-09-16
Pasireotide Therapy in Patients With Nelson's Syndrome
Pasireotide - Nelson Syndrome
Phase 2TerminatedSheffield Teaching Hospitals NHS Foundation Trust82011-03-012016-11-02
Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
Farletuzumab - Resectable, Non-functioning Pituitary Adenoma
Phase 2WithdrawnMorphotek2011-02-012013-11-04
Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas
Pasireotide, cabergoline - Non-functioning Pituitary Adenomas, Prolactinomas
Phase 2 / Phase 3CompletedUniversidade Federal do Rio de Janeiro212010-03-012016-08-22
Temozolomide in Treating Patients With Invasive Pituitary Tumors
temozolomide, DNA methylation analysis, microarray analysis - Brain and Central Nervous System Tumors
Phase 2WithdrawnJonsson Comprehensive Cancer Center2009-12-012020-07-31
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
pasireotide LAR - Pancreatic Neoplasm, Pituitary Neoplasm
Phase 2TerminatedNovartis Pharmaceuticals1182009-09-012016-07-26
Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
Lapatinib - Pituitary Adenomas, Prolactinomas
Phase 2CompletedCedars-Sinai Medical Center92009-07-012020-01-22
Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas
pasireotide LAR - Gonadotroph Adenomas
Phase 2TerminatedUniversity of Pennsylvania22009-06-012017-11-28
Rosiglitazone in Treating Patients With Pituitary Tumors
rosiglitazone maleate - Brain and Central Nervous System Tumors
Phase 2TerminatedJonsson Comprehensive Cancer Center12006-10-012020-08-14

Showing 20 of 25. Sign in to see all of them.

Narrower conditions

Prolactinoma (5)  ·  Acromegaly (2)  ·  Brain Neoplasms (2)  ·  Central Nervous System Neoplasms (2)  ·  Growth Hormone-Secreting Pituitary Adenoma (2)  ·  Meningioma (2)  ·  Nelson Syndrome (2)  ·  Pituitary Diseases (2)  ·  ACTH Syndrome, Ectopic (1)  ·  Adenoma, Acidophil (1)  ·  Adenoma, Basophil (1)  ·  Adenoma, Chromophobe (1)  ·  Adrenocortical Hyperfunction (1)  ·  Astrocytoma (1)

Broader conditions

Brain Diseases (25)  ·  Central Nervous System Diseases (25)  ·  Endocrine Gland Neoplasms (25)  ·  Endocrine System Diseases (25)  ·  Hypothalamic Diseases (25)  ·  Neoplasms (25)  ·  Neoplasms by Site (25)  ·  Nervous System Diseases (25)  ·  Pituitary Diseases (23)  ·  Hypothalamic Neoplasms (21)  ·  Nervous System Neoplasms (21)  ·  Supratentorial Neoplasms (21)  ·  Brain Neoplasms (19)  ·  Central Nervous System Neoplasms (19)  ·  Neoplasms by Histologic Type (10)

Interventions

pasireotide (6)  ·  Temozolomide (3)  ·  Cabergoline (2)  ·  Biological Therapy (1)  ·  Capecitabine (1)  ·  Clomiphene (1)  ·  Complementary Therapies (1)  ·  DNA Methylation (1)  ·  Ipilimumab (1)  ·  Lapatinib (1)  ·  Microarray Analysis (1)  ·  Nivolumab (1)  ·  Radiotherapy (1)  ·  Rosiglitazone (1)  ·  TBR-760 (1)

Sponsors

Novartis Pharmaceuticals (3)  ·  Columbia University (2)  ·  Jonsson Comprehensive Cancer Center (2)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2)  ·  Burzynski Research Institute (1)  ·  Cedars-Sinai Medical Center (1)  ·  Endocyte (1)  ·  Federal University of São Paulo (1)  ·  Harry T Whelan, MD (1)  ·  M.D. Anderson Cancer Center (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  Morphotek (1)  ·  Peking Union Medical College Hospital (1)  ·  Sheffield Teaching Hospitals NHS Foundation Trust (1)  ·  Tiburio Therapeutics (1)

Countries

United States (16)  ·  Brazil (4)  ·  Germany (3)  ·  Argentina (2)  ·  France (2)  ·  Italy (2)  ·  Mexico (2)  ·  Spain (2)  ·  Australia (1)  ·  Belgium (1)  ·  Canada (1)  ·  Colombia (1)  ·  Greece (1)  ·  Hungary (1)  ·  India (1)

Top investigators

Anthony Heaney, MD (2)  ·  Andrew Lin, MD (1)  ·  Brent Senior, MD (1)  ·  Bruce Wallin, MD (1)  ·  Camilo Jimenez (1)  ·  Gabrielle Page-Wilson, M.D. (1)  ·  Harry T Whelan, MD (1)  ·  Joanna Klubo-Gwiezdzinska, M.D. (1)  ·  John Newell-Price (1)  ·  Julio Abucham, MD, PhD (1)  ·  Nelson Oyesiku, MD (1)  ·  Nelson Oyesiku, MD, PhD, FACS (1)  ·  Odelia Cooper, MD (1)

Results publications

PMID 29313180, PMID 33150390, PMID 33362722, PMID 35954244, PMID 36856733, PMID 37715962, PMID 37876540

NIH funding

2008 (1), 2009 (1), R21DK112093 (1)